Unichem Laboratories (NSE:UNICHEMLAB) LT-Debt-to-Total-Asset : 0.02 (As of Sep. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Unichem Laboratories LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Unichem Laboratories's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.02.

Unichem Laboratories's long-term debt to total assets ratio declined from Sep. 2023 (0.02) to Sep. 2024 (0.02). It may suggest that Unichem Laboratories is progressively becoming less dependent on debt to grow their business.

Unichem Laboratories LT-Debt-to-Total-Asset Historical Data

The historical data trend for Unichem Laboratories's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Unichem Laboratories LT-Debt-to-Total-Asset Chart

Unichem Laboratories Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.03

0.02

Unichem Laboratories Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.02	-	0.02	-	0.02

Unichem Laboratories LT-Debt-to-Total-Asset Calculation

Unichem Laboratories's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	623.747	/	31693.441
	=	0.02

Unichem Laboratories's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	514.5	/	33109.6
	=	0.02

Unichem Laboratories (NSE:UNICHEMLAB) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Unichem Laboratories LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Unichem Laboratories's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Unichem Laboratories Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Unichem Laboratories Ltd (NSE:UNICHEMLAB) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

506690:India

Address

Off. S. V. Road, Unichem Bhavan, Prabhat Estate, Jogeshwari (West), Mumbai, MH, IND, 400 102

Website

https://www.unichemlabs.com

Unichem Laboratories Ltd is an India based pharmaceutical company. It manufactures a range of Active Pharmaceutical Ingredients (APIs). The company's products are offered in the areas of gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. Some of its products include Apixaban, Brimonidine Tartrate, Finofibrate, Glipizide, Piroxicam and others. The company has a global market presence with sales in India and outside India, and the majority of the revenue derived from India. Its product categories comprises Formulations and Bulk Drugs and Chemicals.

Unichem Laboratories Headlines

No Headlines